Development of granulomatous hepatitis during treatment with interferon-alpha 2b.
Propst
A
A
Propst
T
T
Dietze
O
O
Kathrein
H
H
Judmeier
G
G
Vogel
W
W
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology; D006099:Granuloma / Q000139:chemically induced* / Q000473:pathology; D006509:Hepatitis B / Q000150:complications / Q000628:therapy; D006526:Hepatitis C / Q000150:complications / Q000628:therapy; D006521:Hepatitis, Chronic / Q000150:complications / Q000628:therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008099:Liver / Q000473:pathology; D008107:Liver Diseases / Q000473:pathology; D008297:Male; D011994:Recombinant Proteins
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins